论文部分内容阅读
目的 探讨雌激素调节蛋白PS2 在乳腺癌中的表达及其临床意义。方法 应用免疫组化S P法 ,对 4 8例人乳腺浸润性导管癌中PS2 进行检测 ,分析其与ER ,PR以及预后的关系。结果 PS2 与ER呈显著正相关。在ER(+)PR(+)的病人中 ,PS2 阳性率达 6 7 9% ,而在ER(- )PR(- )的病人中PS2 阳性率仅为 12 5 % ,二者相比有显著性差异 (P <0 .0 1)。PS2 阳性表达与病人长生存期呈正相关 ,与腋窝淋巴结转移无相关性。结论 在预测乳腺癌抗雌激素治疗的效果时 ,PS2 要优于ER ,PR。同时PS2 阳性的乳腺癌患者预后较好 ,PS2 可作为预测乳腺癌患者生物学行为的指标之一
Objective To investigate the expression of estrogen regulatory protein PS2 in breast cancer and its clinical significance. Methods Immunohistochemical SP method was used to detect the expression of PS2 in 48 cases of invasive ductal carcinoma of human breast and its relationship with ER, PR and prognosis. Results There was a significant positive correlation between PS2 and ER. The positive rate of PS2 in patients with ER (+) PR (+) was 67.9%, while the positive rate of PS2 in patients with ER (-) PR (-) was only 125% Sex differences (P <0.01). The positive expression of PS2 was positively correlated with the long-term survival of patients and had no correlation with the axillary lymph node metastasis. Conclusions PS2 is superior to ER and PR in predicting the anti-estrogen effect of breast cancer. At the same time PS2-positive breast cancer patients with good prognosis, PS2 can be used as one of the indicators to predict the biological behavior of breast cancer patients